Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations

被引:95
作者
Arendrup, Maiken Cavling [1 ]
Perlin, David S. [2 ]
Jensen, Rasmus Hare [1 ]
Howard, Susan Julie [3 ]
Goodwin, Joanne [3 ]
Hope, William [3 ]
机构
[1] Statens Serum Inst, Unit Mycol & Parasitol, DK-2300 Copenhagen, Denmark
[2] UMDNJ New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ USA
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester, Lancs, England
基金
美国国家卫生研究院;
关键词
INVASIVE CANDIDIASIS; REDUCED SUSCEPTIBILITY; AMPHOTERICIN-B; ALBICANS; TROPICALIS; ECHINOCANDINS; SUBSTITUTIONS; EPIDEMIOLOGY; ESOPHAGITIS; FLUCONAZOLE;
D O I
10.1128/AAC.06369-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half-and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E(50)s) were 194.2 and 53.99 mg . h/liter, respectively. In contrast, the maximum effect (E-max) for caspofungin was higher against S3 than R83, but the estimates for E-50 were similar (187.1 and 203.5 mg . h/liter, respectively). Anidulafungin failed to induce a >= 1-log reduction for any of the isolates (AUC range, 139 to 557 mg . h/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.
引用
收藏
页码:2435 / 2442
页数:8
相关论文
共 45 条
  • [1] In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
    Andes, D.
    Diekema, D. J.
    Pfaller, M. A.
    Bohrmuller, J.
    Marchillo, K.
    Lepak, A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) : 2497 - 2506
  • [2] [Anonymous], 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts
  • [3] Third Informational Supplement. CLSI document M27-S3, P28
  • [4] Epidemiology of invasive candidiasis
    Arendrup, Maiken C.
    [J]. CURRENT OPINION IN CRITICAL CARE, 2010, 16 (05) : 445 - 452
  • [5] Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
    Arendrup, Maiken Cavling
    Sulim, Sofia
    Holm, Anette
    Nielsen, Lene
    Nielsen, Susanne Dam
    Knudsen, Jenny Dahl
    Drenck, Niels Erik
    Christensen, Jens Jorgen
    Johansen, Helle Krogh
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (09) : 3300 - 3308
  • [6] Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type and fks Hot Spot Mutant Candida Isolates
    Arendrup, Maiken Cavling
    Park, Steven
    Brown, Steven
    Pfaller, Michael
    Perlin, David S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) : 1891 - 1895
  • [7] Echinocandin Susceptibility Testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots
    Arendrup, Maiken Cavling
    Rodriguez-Tudela, Juan-Luis
    Park, Steven
    Garcia-Effron, Guillermo
    Delmas, Guillaume
    Cuenca-Estrella, Manuel
    Gomez-Lopez, Alicia
    Perlin, David S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (04) : 1580 - 1587
  • [8] Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media
    Arendrup, Maiken Cavling
    Garcia-Effron, Guillermo
    Lass-Floerl, Cornelia
    Gomez Lopez, Alicia
    Rodriguez-Tudela, Juan-Luis
    Cuenca-Estrella, Manuel
    Perlin, David S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 426 - 439
  • [9] Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing
    Arendrup, Maiken Cavling
    Garcia-Effron, Guillermo
    Buzina, Walter
    Mortensen, Klaus Leth
    Reiter, Nanna
    Lundin, Christian
    Jensen, Henrik Elvang
    Lass-Florl, Cornelia
    Perlin, David S.
    Bruun, Brita
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) : 1185 - 1193
  • [10] Acquired resistance to echinocandins in Candida albicans:: case report and review
    Baixench, Marie-Therese
    Aoun, Naji
    Desnos-Ollivier, Marie
    Garcia-Hermoso, Dea
    Bretagne, Stephane
    Ramires, Sandrine
    Piketty, Christophe
    Dannaoui, Eric
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (06) : 1076 - 1083